ARRDC3 and neoplasm: We observed a remarkable (statistically significant) decrease in tumour latency in mice reconstituted with Eμ-MycT/+;Arrdc3−/− foetal liver cells (median survival = 67 days) compared to recipients reconstituted with Eμ-MycT/+;Arrdc3+/+ foetal liver cells (median survival = 210 days) (Mantel-Cox test, df = 1, X2 = 13.22, p < 0.001 (p = 0.000276)) (Fig. 4C).